314 related articles for article (PubMed ID: 23311243)
1. [Assessment of recombinant human thyrotropin application in following-up patients with well-differentiated thyroid carcinoma].
Rajkovaca Z; Kovacević P; Stanetić M; Ristić S
Vojnosanit Pregl; 2012 Nov; 69(11):941-6. PubMed ID: 23311243
[TBL] [Abstract][Full Text] [Related]
2. Recombinant human TSH changes the multidisciplinary approach to patients with differentiated thyroid carcinoma. Two-year experience.
Giusti M; Zoccola R; Guazzini B; Molinari E; Valenti S; Villa G; Bertolazzi L; Minuto F
Minerva Endocrinol; 2003 Sep; 28(3):191-203. PubMed ID: 14605601
[TBL] [Abstract][Full Text] [Related]
3. The use of recombinant human TSH in the follow-up of differentiated thyroid cancer: experience from a large patient cohort in a single centre.
Giovanni V; Arianna LG; Antonio C; Francesco F; Michele K; Giovanni S; Marco S; Giovanni L
Clin Endocrinol (Oxf); 2002 Feb; 56(2):247-52. PubMed ID: 11874417
[TBL] [Abstract][Full Text] [Related]
4. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
[TBL] [Abstract][Full Text] [Related]
5. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
6. The diagnostic use of the rhTSH/thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels.
Pellegriti G; Scollo C; Regalbuto C; Attard M; Marozzi P; Vermiglio F; Violi MA; Cianci M; Vigneri R; Pezzino V; Squatrito S
Clin Endocrinol (Oxf); 2003 May; 58(5):556-61. PubMed ID: 12699436
[TBL] [Abstract][Full Text] [Related]
7. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of administration of rhTSH with withdrawal of thyroid hormone. Follow-up of patients with differentiated thyroid carcinoma].
Caresia AP; Castell Conesa J; Obiols Alfonso G; Pifarré Montaner P; Negre Busó M; García Alonso C; Galofré Mora P; Mesa Manteca J
Rev Esp Med Nucl; 2006; 25(4):236-41. PubMed ID: 16827986
[TBL] [Abstract][Full Text] [Related]
9. [Application of recombinant human TSH in the diagnostic protocol of differentiated thyroid carcinoma].
Jiménez-Hoyuela García JM; García Almeida JM; Delgado García A; Aguilar Fernández I; Martínez del Valle Torres MD; Ortega Lozano S; Rebollo Aguirre A; Mancha Doblas I; Pinzón Martín JL; Picón César MJ; Zamorano Vázquez D
Rev Esp Med Nucl; 2005; 24(3):152-60. PubMed ID: 15847782
[TBL] [Abstract][Full Text] [Related]
10. Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer.
Torlontano M; Crocetti U; D'Aloiso L; Bonfitto N; Di Giorgio A; Modoni S; Valle G; Frusciante V; Bisceglia M; Filetti S; Schlumberger M; Trischitta V
Eur J Endocrinol; 2003 Jan; 148(1):19-24. PubMed ID: 12534353
[TBL] [Abstract][Full Text] [Related]
11. Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone.
David A; Blotta A; Bondanelli M; Rossi R; Roti E; Braverman LE; Busutti L; degli Uberti EC
J Nucl Med; 2001 Oct; 42(10):1470-5. PubMed ID: 11585859
[TBL] [Abstract][Full Text] [Related]
12. Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH.
Lippi F; Capezzone M; Angelini F; Taddei D; Molinaro E; Pinchera A; Pacini F
Eur J Endocrinol; 2001 Jan; 144(1):5-11. PubMed ID: 11174831
[TBL] [Abstract][Full Text] [Related]
13. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.
Golger A; Fridman TR; Eski S; Witterick IJ; Freeman JL; Walfish PG
J Endocrinol Invest; 2003 Oct; 26(10):1023-31. PubMed ID: 14759077
[TBL] [Abstract][Full Text] [Related]
14. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
[TBL] [Abstract][Full Text] [Related]
15. Recombinant human thyrotropin in follow-up of patients with differentiated thyroid cancer.
Podoba J
Bratisl Lek Listy; 2010; 111(1):38-40. PubMed ID: 20429310
[TBL] [Abstract][Full Text] [Related]
16. Clinical value of different responses of serum thyroglobulin to recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma.
David A; Blotta A; Rossi R; Zatelli MC; Bondanelli M; Roti E; Braverman LE; Busutti L; degli Uberti EC
Thyroid; 2005 Feb; 15(2):158-64. PubMed ID: 15753676
[TBL] [Abstract][Full Text] [Related]
17. Compliance with follow-up and the informative value of diagnostic whole-body scan in patients with differentiated thyroid carcinoma given recombinant human TSH.
Cohen O; Dabhi S; Karasik A; Zila Zwas S
Eur J Endocrinol; 2004 Mar; 150(3):285-90. PubMed ID: 15012612
[TBL] [Abstract][Full Text] [Related]
18. Recombinant human thyrotropin (rhTSH) in the follow-up and treatment of patients with thyroid cancer.
Bombardieri E; Seregni E; Villano C; Aliberti G; Mattavelli F
Tumori; 2003; 89(5):533-6. PubMed ID: 14870779
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy.
Torlontano M; Crocetti U; Augello G; D'Aloiso L; Bonfitto N; Varraso A; Dicembrino F; Modoni S; Frusciante V; Di Giorgio A; Bruno R; Filetti S; Trischitta V
J Clin Endocrinol Metab; 2006 Jan; 91(1):60-3. PubMed ID: 16219716
[TBL] [Abstract][Full Text] [Related]
20. Value of diagnostic radioiodine scintigraphy and thyroglobulin measurements after rhTSH injection.
Verburg FA; de Keizer B; de Klerk JM; Lentjes EG; Lips CJ; van Isselt JW
Nuklearmedizin; 2009; 48(1):26-9. PubMed ID: 19212608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]